1 BTC
=
- USD
Medpace Holdings, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Medpace Holdings, Inc. Common Stock
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Market Statistics
Trading Metrics
How to Buy MEDP
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MEDP
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesA securities class action lawsuit has been filed against Medpace Holdings, Inc. alleging that defendants made false and misleading statements regarding the company's backlog cancellation rates. The lawsuit claims defendants misrepresented cancellation rates as 'well behaved' and provided overly positive growth expectations that could not be sustained. Investors with losses exceeding $100,000 are encouraged to join the class action before the June 8, 2026 lead plaintiff deadline.
Rosen Law Firm has filed class action lawsuits against Veritone, Inc., Medpace Holdings, Inc., and Stellantis N.V. on behalf of investors who suffered losses. Veritone is accused of inaccurately recording revenue and costs, overstating financial metrics, and maintaining deficient internal controls, leading to required financial restatements. Investors who purchased securities during specified class periods may be eligible for compensation.
Rosen Law Firm is soliciting investors who suffered losses in Medpace Holdings, Stellantis N.V., and Blaize Holdings to join securities class action lawsuits. The Medpace case alleges the company made false statements about backlog cancellation rates and provided misleading growth projections. The lead plaintiff deadline for Medpace is June 8, 2026.
A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the company's book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.
Rosen Law Firm is reminding investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 of the June 8, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, providing overly positive growth expectations that could not be sustained.